CoVac501, a Self-Adjuvanting Peptide Vaccine Conjugated with TLR7 Agonists, against SARS-CoV-2 Induces Protective Immunity

In non-human primates, CoVac501 elicited high and persistent titers of protective neutralizing antibodies against multiple receptor-binding domain mutations, SARS-CoV-2 original strain, and variants.